Curated News
By: NewsRamp Editorial Staff
November 04, 2026
Lonza CEO to Present at Jefferies Healthcare Conference
TLDR
- Lonza offers investors direct access to CEO Wolfgang Wienand's strategy at the Jefferies conference, with a 90-day webcast replay for advantage.
- Lonza CEO Wolfgang Wienand presents and answers questions on 18 November from 15:30 to 15:55 GMT, with a live webcast and replay available.
- Lonza's conference participation supports its CDMO work, helping pharma and biotech partners turn innovations into life-saving therapies for patients worldwide.
- Lonza, a leading CDMO with CHF 3.4 billion in half-year 2026 sales, will webcast its Jefferies presentation live and offer a 90-day replay.
Impact - Why it Matters
Lonza’s participation in the Jefferies Global Healthcare Conference provides a key platform for CEO Wolfgang Wienand to directly address investors and stakeholders, offering insights into the company’s strategy and performance. As a leading CDMO, Lonza plays a critical role in the healthcare ecosystem, helping pharma and biotech companies bring therapies to market. The webcast and replay ensure broad access to this information, which can influence investment decisions and shape perceptions of Lonza’s growth trajectory. For patients and partners, Lonza’s continued engagement with the investment community underscores its commitment to advancing life-saving treatments and maintaining robust manufacturing capabilities.
Summary
Lonza, the world’s leading contract development and manufacturing organization (CDMO), has announced its participation in the Jefferies Global Healthcare Conference in London on 17 and 18 November 2026. The conference will feature a presentation and Q&A session hosted by Lonza CEO Wolfgang Wienand on 18 November from 15:30 to 15:55 GMT (16:30 to 16:55 CET). This session will be webcast live, and a replay will be available on the Lonza Investor Relations website for 90 days. Investors and interested parties can access the live audio webcast via this link.
Lonza is dedicated to serving the healthcare industry, working across three continents with a global team of approximately 17,000 colleagues. The company partners with pharma and biotech companies to turn breakthrough innovations into viable therapies, enabling customers to bring life-saving and life-enhancing treatments to patients worldwide. In Half-Year 2026, Lonza generated sales of CHF 3.4 billion with a CORE EBITDA of CHF 1.2 billion. More information about the company can be found at www.lonza.com. The original release is available on www.newmediawire.com.
Source Statement
This curated news summary relied on content distributed by NewMediaWire. Read the original source here, Lonza CEO to Present at Jefferies Healthcare Conference
